Practical Geriatrics ›› 2026, Vol. 40 ›› Issue (4): 325-331.doi: 10.3969/j.issn.1003-9198.2026.04.001
JI Junjie, ZHOU Zhonghan, LIU Gongyue, LIU Yixi, LIAO Limin
Online:2026-04-23
Published:2026-04-23
Contact:
LIAO Limin,Email:lmliao1964@163.com
CLC Number:
JI Junjie, ZHOU Zhonghan, LIU Gongyue, LIU Yixi, LIAO Limin. Correlation between frailty and the risk of benign prostatic hyperplasia/lower urinary tract symptoms in elderly males aged 60 and above in China[J]. Practical Geriatrics, 2026, 40(4): 325-331.
| [1] LERNER L B, MCVARY K T, BARRY M J, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia:AUA GUIDELINE PART Ⅱ-Surgical Evaluation and Treatment[J]. J Urol, 2021, 206(4):818-826. [2] NGUYEN D D, LI T, FERREIRA R, et al. Ablative minimally invasive surgical therapies for benign prostatic hyperplasia:a review of Aquablation, Rezum, and transperineal laser prostate ablation[J]. Prostate Cancer Prostatic Dis, 2024, 27(1):22-28. [3] LIU T T, PASCAL L E, RICKE E A, et al. Estrogen regulation in the prostate underlies racial disparity in men with benign prostatic hyperplasia[J]. J Pathol, 2026, 268(2):176-187. [4] WANG W, GUO Y, ZHANG D, et al. The prevalence of benign prostatic hyperplasia in mainland China:evidence from epidemiological surveys[J]. Sci Rep, 2015, 5:13546. [5] YE L, LIANG R, LIU X, et al. Frailty and sarcopenia:a bibliometric analysis of their association and potential targets for intervention[J]. Ageing Res Rev, 2023, 92:102111. [6] QIU Y, LI G, WANG X, et al. Prevalence of multidimensional frailty among community-dwelling older adults:a systematic review and meta-analysis[J]. Int J Nurs Stud, 2024, 154:104755. [7] TREACY D, HASSETT L, SCHURR K, et al. Mobility training for increasing mobility and functioning in older people with frailty[J]. Cochrane Database Syst Rev, 2022, 6(6):CD010494. [8] VERONESE N, CUSTODERO C, CELLA A, et al. Prevalence of multidimensional frailty and pre-frailty in older people in different settings:a systematic review and meta-analysis[J]. Ageing Res Rev, 2021, 72:101498. [9] IMAM T, KONSTANT-HAMBLING R, FLUCK R, et al. The hospital frailty risk score-outcomes in specialised services[J]. Age Ageing, 2021, 50(2):511-518. [10] CAO X, YANG Z, LI X, et al. Association of frailty with the incidence risk of cardiovascular disease and type 2 diabetes mellitus in long-term cancer survivors:a prospective cohort study[J]. BMC Med, 2023, 21(1):74. [11] TAYLOR-ROWAN M, HAFDI M, DROZDOWSKA B, et al. Physical and brain frailty in ischaemic stroke or TIA:shared occurrence and outcomes. A cohort study[J]. Eur Stroke J, 2023, 8(4):1011-1020. [12] YANG H, OU F, CHANG Q, et al. Physical frailty, genetic predisposition, and the risks of severe non-alcoholic fatty liver disease and cirrhosis:a cohort study[J]. J Cachexia Sarcopenia Muscle, 2024, 15(4):1491-1500. [13] BAUER S R, WALTER L C, ENSRUD K E, et al. Assessment of frailty and association with progression of benign prostatic hyperplasia symptoms and serious adverse events among men using drug therapy[J]. JAMA Netw Open, 2021, 4(11):e2134427. [14] KÖNIG M, MALSCH C, MARIÑO J, et al. Nocturia as a clinical marker of loss of function and resilience or risk factor for frailty in older adults? Results of the Berlin Aging Study II[J]. Geroscience, 2025, 47(3):4139-4151. [15] HE D, LI J, LI Y, et al. Frailty is associated with the progression of prediabetes to diabetes and elevated risks of cardiovascular disease and all-cause mortality in individuals with prediabetes and diabetes:evidence from two prospective cohorts[J]. Diabetes Res Clin Pract, 2022, 194:110145. [16] XU W, CAI J, LIU Y, et al. Sarcopenia and frailty among older Chinese adults:Findings from the CHARLS study[J]. PLoS One, 2024, 19(11):e0312879. [17] ZHANG W, DING Z, PENG Y, et al. LUTS/BPH increases the risk of depressive symptoms among elderly adults:a 5-year longitudinal evidence from CHARLS[J]. J Affect Disord, 2024, 367:210-218. [18] ZHOU Z, LIU G, JI J, et al. Association of sarcopenic obesity with benign prostatic hyperplasia/lower urinary tract symptoms:a nationwide cross-sectional study[J]. Eur Urol Open Sci, 2025, 82:81-87. [19] ALBERTI K G M M, ZIMMET P, SHAW J, et al. The metabolic syndrome:a new worldwide definition[J]. Lancet, 2005, 366(9491):1059-1062. [20] CHEN L K, WOO J, ASSANTACHAI P, et al. Asian working group for sarcopenia:2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21(3):300-307.e2. [21] WANG J, SUN Y X, XIANG S, et al. The association between blood heavy metals and gallstones:a cross-sectional study[J]. Sci Total Environ, 2023, 904:166735. [22] ABREU W, TOLSON D, JACKSON G A, et al. The relationship between frailty, functional dependence, and healthcare needs among community-dwelling people with moderate to severe dementia[J]. Health Soc Care Community, 2019, 27(3):642-653. [23] DIDIER J, DE LANDTSHEER S, PACHECO M P, et al. Clinical data-driven classification of pre-frailty reveals sex-specific patterns - Data from the Berlin Aging Study II (BASE-II)[J]. Mech Ageing Dev, 2025, 228:112114. [24] BAUER S R, SCHERZER R, SUSKIND A M, et al. Co-occurrence of lower urinary tract symptoms and frailty among community-dwelling older men[J]. J Am Geriatr Soc, 2020, 68(12):2805-2813. [25] BAUER S R, MCCULLOCH C E, CAWTHON P M, et al. Longitudinal associations between concurrent changes in phenotypic frailty and lower urinary tract symptoms among older men[J]. J Frailty Aging, 2023, 12(2):117-125. [26] BELLOS T C, TZELVES L I, MANOLITSIS I S, et al. Frailty and benign prostatic hyperplasia:the thrilling underlying impact[J]. Arch Ital Urol Androl, 2022, 94(3):345-349. [27] REN X, WANG J, WANG Z, et al. Frailty as a risk marker of adverse lower urinary symptom outcomes in patients with benign prostatic hyperplasia undergoing transurethral resection of prostate[J]. Front Med:Lausanne, 2023, 10:1185539. [28] PARKER-AUTRY C Y, BAUER S, FORD C, et al. Examining the role of frailty on treatment patterns and complications among older women undergoing procedure-based treatment for urinary incontinence[J]. J Gerontol A Biol Sci Med Sci, 2024, 79(6):glae027. [29] BROMAN M M, LANMAN N A, VICKMAN R E, et al. Immune cell single-cell RNA sequencing analyses link an age-associated T cell subset to symptomatic benign prostatic hyperplasia[J]. Front Immunol, 2025, 16:1585446. [30] FU X, WANG Y, LU Y, et al. Association between metabolic syndrome and benign prostatic hyperplasia:the underlying molecular connection[J]. Life Sci, 2024, 358:123192. [31] GU M, GE J, XU H, et al. Arctigenin inhibits high glucose-induced EMT and cell proliferation to alleviate benign prostatic hyperplasia companied with type 2 diabetes mellitus through MBOAT4/acylated Ghrelin/GHS-R[J]. Chem Biol Interact, 2025, 418:111601. [32] YANG T, QIU Z, SHEN J, et al. 17β-Estradiol, through activating the G protein-coupled estrogen receptor, exacerbates the complication of benign prostatic hyperplasia in type 2 diabetes mellitus patients by inducing prostate proliferation[J]. J Pharm Anal, 2024, 14(9):100962. [33] SI H, JIN Y, QIAO X, et al. Predictive performance of 7 frailty instruments for short-term disability, falls and hospitalization among Chinese community-dwelling older adults:a prospective cohort study[J]. Int J Nurs Stud, 2021, 117:103875. [34] CHEN W, MAN S, WANG B, et al. Metabolically healthy obesity is associated with increased risk of lower urinary tract symptoms secondary to benign prostatic hyperplasia:a cohort study of Chinese elderly males[J]. Low Urin Tract Symptoms, 2022, 14(3):170-177. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
|